医药板块震荡回调，资金逆势布局，港股通创新药ETF易方达(159316)全天净申购达3400万份

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a downturn in stock indices, yet there is significant capital inflow into innovative drug ETFs, indicating a potential investment opportunity in the long term [1]. Group 1: Market Performance - The CSI Hong Kong Stock Connect Healthcare Comprehensive Index fell by 4.7%, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 4.3% [1]. - The CSI Innovative Drug Industry Index declined by 1.5%, and the CSI Biotechnology Theme Index dropped by 1.2% [1]. - The CSI 300 Healthcare Index saw a smaller decline of 0.8% [1]. - Despite the overall market downturn, the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) recorded a net subscription of 34 million units throughout the day [1]. Group 2: Industry Growth and Valuation - The total value of License-out transactions for Chinese innovative drugs has increased from $2.562 billion in 2017 to $140.274 billion by 2025, reflecting enhanced international competitiveness [1]. - By 2025, over 70% of innovative drug companies are expected to achieve positive revenue growth, indicating that the industry is entering a commercialization phase [1]. - The current valuation of the pharmaceutical sector is considered attractive, with recommendations to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1].